Braf inhibitor drugs

BRAF inhibitors are drugs that can shrink or slow the growth of metastatic melanoma in people whose tumors have a BRAF mutation.

by H Liu 2024 Cited by 35Moreover, drug resistance to BRAF inhibitor treatment also appears to be an important issue. Considering the successful use of BRAF inhibitors

Similarly, BRAF gene testing is important in the selection of patients with melanoma who could benefit from BRAF inhibitor therapies.

The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice.

A variety of new generation inhibitors that do not show paradoxical activation have been developed. Alternatively, efforts have begun to develop inhibitors targeting the dimer interface of BRAF. A deeper understanding of BRAF regulation together with more diverse BRAF inhibitors will be beneficial for drug development in RAF or RASdriven cancers.

BRAF inhibitors. Vemurafenib (Zelboraf), dabrafenib (Tafinlar), and encorafenib (Braftovi) are drugs that target the BRAF protein directly.

by J Kaltwasser 2024Dabrafenib is a BRAF inhibitor, and trametinib is a MEK inhibitor. The FDA approved the combination therapy in 2024 for patients with BRAF

BRAF inhibitors. BRAF inhibitors include vemurafenib and dabrafenib. Cutaneous adverse effects are common. Hyperkeratotic keratinocytic lesions. Cutaneous

BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what they expected.